2,414,645 Shares in Johnson & Johnson (NYSE:JNJ) Bought by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,414,645 shares of the company's stock, valued at approximately $349,206,000. Johnson & Johnson makes up about 0.7% of Universal Beteiligungs und Servicegesellschaft mbH's investment portfolio, making the stock its 20th biggest position. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.10% of Johnson & Johnson as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in JNJ. Tallon Kerry Patrick acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $290,000. Capital & Planning LLC increased its stake in Johnson & Johnson by 13.6% during the 4th quarter. Capital & Planning LLC now owns 1,528 shares of the company's stock worth $221,000 after buying an additional 183 shares in the last quarter. Cetera Trust Company N.A raised its holdings in shares of Johnson & Johnson by 13.5% during the fourth quarter. Cetera Trust Company N.A now owns 1,923 shares of the company's stock valued at $278,000 after acquiring an additional 229 shares during the last quarter. Westside Investment Management Inc. lifted its position in shares of Johnson & Johnson by 13.3% in the fourth quarter. Westside Investment Management Inc. now owns 4,859 shares of the company's stock valued at $703,000 after acquiring an additional 570 shares in the last quarter. Finally, Kelleher Financial Advisors boosted its stake in shares of Johnson & Johnson by 2.6% in the fourth quarter. Kelleher Financial Advisors now owns 6,516 shares of the company's stock worth $942,000 after acquiring an additional 165 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 0.5%

Shares of JNJ traded down $0.72 during trading on Wednesday, reaching $152.53. 8,423,290 shares of the company traded hands, compared to its average volume of 7,963,219. The stock has a 50-day simple moving average of $154.85 and a 200-day simple moving average of $153.65. The stock has a market cap of $367.00 billion, a PE ratio of 22.94, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. On average, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.41%. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Barclays decreased their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Bank of America decreased their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. Finally, Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.